Background/Aims: To enable the diagnosis of moyamoya disease (MMD), detection of distal internal carotid artery stenosis and hazy network of basal collaterals (BCs) are required. This study aimed at evaluating the factors that could determine the degree of BCs in patients with angiographically confirmed MMD. Methods: We analyzed 146 consecutive patients with MMD (age 26.2 ± 19.6, range 1-75). The degree of BCs (%) was measured based on conventional angiography. Factors associated with the degree of BCs, including clinico-radiological and genetic factors (p.Arg4810Lys variant), were analyzed. Results: The degree of BCs varied among MMD patients and significantly decreased with an increase in the age of diagnosis of MMD (coefficient -1.55; p < 0.001). Although the degree of BC development depends on the MMD stage (Suzuki stage), it is less prominent in adult-onset (>18 years) MMD compared to childhood MMD. The presence of p.Arg4810Lys variant, types of MMD (bilateral vs. unilateral) and stroke (ischemic, hemorrhagic, or asymptomatic), shrinkage (outer diameter) of intracranial vessels, external carotid collateral status, and cortical neovascularization were not associated with the degree of BCs. Conclusion: Although prominent BCs are required for diagnosis of MMD, BCs are decreased with aging, suggesting that angiogenic capacity is altered in adult onset MMD compared to childhood MMD.

Keywords:
Genetics, Intracranial stenosis, Collaterals, Moyamoya, Stroke
1.
Suzuki J, Takaku A: Cerebrovascular ‘moyamoya' disease. Disease showing abnormal net-like vessels in base of brain. Arch Neurol 1969;20:288-299.
2.
Kuroda S, Houkin K: Moyamoya disease: current concepts and future perspectives. Lancet Neurol 2008;7:1056-1066.
3.
Bang OY, Fujimura M, Kim SK: The pathophysiology of moyamoya disease: an update. J Stroke 2016;18:12-20.
4.
Fukui M: Guidelines for the diagnosis and treatment of spontaneous occlusion of the circle of willis (‘moyamoya' disease). Research committee on spontaneous occlusion of the circle of willis (moyamoya disease) of the ministry of health and welfare, Japan. Clin Neurol Neurosurg 1997;99(suppl 2):S238-S240.
5.
Bang OY, Ryoo S, Kim SJ, Yoon CH, Cha J, Yeon JY, Kim KH, Kim GM, Chung CS, Lee KH, Shin HJ, Ki CS, Jeon P, Kim JS, Hong SC: Adult moyamoya disease: a burden of intracranial stenosis in East Asians? PLoS One 2015;10:e0130663.
6.
Kamada F, Aoki Y, Narisawa A, Abe Y, Komatsuzaki S, Kikuchi A, Kanno J, Niihori T, Ono M, Ishii N, Owada Y, Fujimura M, Mashimo Y, Suzuki Y, Hata A, Tsuchiya S, Tominaga T, Matsubara Y, Kure S: A genome-wide association study identifies RNF213 as the first moyamoya disease gene. J Hum Genet 2011;56:34-40.
7.
Liu W, Morito D, Takashima S, Mineharu Y, Kobayashi H, Hitomi T, Hashikata H, Matsuura N, Yamazaki S, Toyoda A, Kikuta K, Takagi Y, Harada KH, Fujiyama A, Herzig R, Krischek B, Zou L, Kim JE, Kitakaze M, Miyamoto S, Nagata K, Hashimoto N, Koizumi A: Identification of RNF213 as a susceptibility gene for moyamoya disease and its possible role in vascular development. PLoS One 2011;6:e22542.
8.
Ay H, Furie KL, Singhal A, Smith WS, Sorensen AG, Koroshetz WJ: An evidence-based causative classification system for acute ischemic stroke. Ann Neurol 2005;58:688-697.
9.
Henderson RD, Eliasziw M, Fox AJ, Rothwell PM, Barnett HJ: Angiographically defined collateral circulation and risk of stroke in patients with severe carotid artery stenosis. North American symptomatic carotid endarterectomy trial (NASCET) group. Stroke 2000;31:128-132.
10.
Kim SJ, Son TO, Kim KH, Jeon P, Hyun SH, Lee KH, Yeon JY, Kim JS, Hong SC, Shin HJ, Bang OY: Neovascularization precedes occlusion in moyamoya disease: angiographic findings in 172 pediatric patients. Eur Neurol 2014;72:299-305.
11.
Ryoo S, Cha J, Kim SJ, Choi JW, Ki CS, Kim KH, Jeon P, Kim JS, Hong SC, Bang OY: High-resolution magnetic resonance wall imaging findings of moyamoya disease. Stroke 2014;45:2457-2460.
12.
Kim YJ, Lee DH, Kwon JY, Kang DW, Suh DC, Kim JS, Kwon SU: High resolution MRI difference between moyamoya disease and intracranial atherosclerosis. Eur J Neurol 2013;20:1311-1318.
13.
Suzuki J, Kodama N: Moyamoya disease - a review. Stroke 1983;14:104-109.
14.
Kuroda S, Hashimoto N, Yoshimoto T, Iwasaki Y; Research Committee on Moyamoya Disease in Japan: Radiological findings, clinical course, and outcome in asymptomatic moyamoya disease: results of multicenter survey in Japan. Stroke 2007;38:1430-1435.
15.
Nariai T, Matsushima Y, Imae S, Tanaka Y, Ishii K, Senda M, Ohno K: Severe haemodynamic stress in selected subtypes of patients with moyamoya disease: a positron emission tomography study. J Neurol Neurosurg Psychiatry 2005;76:663-669.
16.
Strother MK, Anderson MD, Singer RJ, Du L, Moore RD, Shyr Y, Ladner TR, Arteaga D, Day MA, Clemmons PF, Donahue MJ: Cerebrovascular collaterals correlate with disease severity in adult North American patients with moyamoya disease. AJNR Am J Neuroradiol 2014;35:1318-1324.
17.
Rivard A, Fabre JE, Silver M, Chen D, Murohara T, Kearney M, Magner M, Asahara T, Isner JM: Age-dependent impairment of angiogenesis. Circulation 1999;99:111-120.
18.
Miyatake S, Miyake N, Touho H, Nishimura-Tadaki A, Kondo Y, Okada I, Tsurusaki Y, Doi H, Sakai H, Saitsu H, Shimojima K, Yamamoto T, Higurashi M, Kawahara N, Kawauchi H, Nagasaka K, Okamoto N, Mori T, Koyano S, Kuroiwa Y, Taguri M, Morita S, Matsubara Y, Kure S, Matsumoto N: Homozygous c.14576G>A variant of RNF213 predicts early-onset and severe form of moyamoya disease. Neurology 2012;78:803-810.
19.
Ito A, Fujimura M, Niizuma K, Kanoke A, Sakata H, Morita-Fujimura Y, Kikuchi A, Kure S, Tominaga T: Enhanced post-ischemic angiogenesis in mice lacking RNF213; a susceptibility gene for moyamoya disease. Brain Res 2015;1594:310-320.
20.
Bang OY: Intracranial atherosclerosis: current understanding and perspectives. J Stroke 2014;16:27-35.
21.
Chaturvedi S, Turan TN, Lynn MJ, Kasner SE, Romano J, Cotsonis G, Frankel M, Chimowitz MI: Risk factor status and vascular events in patients with symptomatic intracranial stenosis. Neurology 2007;69:2063-2068.
22.
Chimowitz MI, Lynn MJ, Derdeyn CP, Turan TN, Fiorella D, Lane BF, Janis LS, Lutsep HL, Barnwell SL, Waters MF, Hoh BL, Hourihane JM, Levy EI, Alexandrov AV, Harrigan MR, Chiu D, Klucznik RP, Clark JM, McDougall CG, Johnson MD, Pride GL Jr, Torbey MT, Zaidat OO, Rumboldt Z, Cloft HJ: Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med 2011;365:993-1003.
23.
Natarajan SK, Karmon Y, Tawk RG, Hauck EF, Hopkins LN, Siddiqui AH, Levy EI: Endovascular treatment of patients with intracranial stenosis with moyamoya-type collaterals. J Neurointerv Surg 2011;3:369-374.
24.
Drazin D, Calayag M, Gifford E, Dalfino J, Yamamoto J, Boulos AS: Endovascular treatment for moyamoya disease in a Caucasian twin with angioplasty and wingspan stent. Clin Neurol Neurosurg 2009;111:913-917.
25.
Eicker S, Etminan N, Turowski B, Steiger HJ, Hänggi D: Intracranial carotid artery stent placement causes delayed severe intracranial hemorrhage in a patient with moyamoya disease. J Neurointerv Surg 2011;3:160-162.
26.
Khan N, Dodd R, Marks MP, Bell-Stephens T, Vavao J, Steinberg GK: Failure of primary percutaneous angioplasty and stenting in the prevention of ischemia in moyamoya angiopathy. Cerebrovasc Dis 2011;31:147-153.
27.
Furie KL, Kasner SE, Adams RJ, Albers GW, Bush RL, Fagan SC, Halperin JL, Johnston SC, Katzan I, Kernan WN, Mitchell PH, Ovbiagele B, Palesch YY, Sacco RL, Schwamm LH, Wassertheil-Smoller S, Turan TN, Wentworth D: Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American heart association/American stroke association. Stroke 2011;42:227-276.
28.
Wu Z, Jiang H, Zhang L, Xu X, Zhang X, Kang Z, Song D, Zhang J, Guan M, Gu Y: Molecular analysis of RNF213 gene for moyamoya disease in the Chinese Han population. PLoS One 2012;7:e48179.
29.
Cecchi AC, Guo D, Ren Z, Flynn K, Santos-Cortez RL, Leal SM, Wang GT, Regalado ES, Steinberg GK, Shendure J, Bamshad MJ, Grotta JC, Nickerson DA, Pannu H, Milewicz DM: RNF213 rare variants in an ethnically diverse population with moyamoya disease. Stroke 2014;45:3200-3207.
30.
Ma J, Liu Y, Ma L, Huang S, Li H, You C: RNF213 polymorphism and moyamoya disease: a systematic review and meta-analysis. Neurol India 2013;61:35-39.
31.
Kleinloog R, Regli L, Rinkel GJ, Klijn CJ: Regional differences in incidence and patient characteristics of moyamoya disease: a systematic review. J Neurol Neurosurg Psychiatry 2012;83:531-536.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.